Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
AbbVie’s trenibotulinumtoxinE (TrenibotE), a treatment for glabellar lines, or frown lines, will come up for discussion by a key health ministry panel on October 26. If approved, it would become the first type E botulinum toxin product in Japan. The…
To read the full story
Related Article
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
REGULATORY
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Ueno Warns Against Excessive Mounjaro Prescriptions for Foreign Tourists
October 13, 2026
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…